DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai, based in Woodcliff Lake, NJ, USA, for the production of sterile products.
The agreement covers the production of eribulin mesylate as well as other developmental drugs.
DSM will be a supplier for eribulin mesylate to the US market. Commercial production is anticipated to start in early 2013. L
No financial details were disclosed.
Jens Birgersson becomes new Brenntag CEO
Building on the April 2025 announcement, Dow will take actions across its three operating segments to support European profitability, resulting in the closure of sites in Germany and the UK.
Oxea is returning to its old name and its roots.
Valerie Diele-Braun resigned from her position as CEO and member of the Executive Board of IMCD at the end of April for personal reasons.
Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.
